文献速递瓣膜外科冠心病外科

合并冠心病的主动脉瓣狭窄患者经导管与外科换瓣比较

Transcatheter vs Surgical Aortic Valve Replacement in Medicare Beneficiaries With Aortic Stenosis and Coronary Artery Disease.
PubMed 文献 · Ann Thorac Surg · 2025-01-24

基于美国医保住院索赔数据库2018至2022年数据,纳入65岁以上合并冠心病的主动脉瓣狭窄患者37822例,比较冠脉搭桥联合外科换瓣(CABG+SAVR)与经皮冠脉介入联合经导管换瓣(PCI+TAVR)的围术期及5年结局。PCI+TAVR围术期死亡更低但血管并发症和起搏器植入更高,CABG+SAVR的5年复合终点更优。

要点

  • PCI+TAVR围术期死亡1.1%低于CABG+SAVR的3.6%(OR 0.29,P<.001)。
  • PCI+TAVR血管并发症(OR 6.02)和新永久起搏器(OR 1.92)风险更高。
  • 5年卒中、心梗、瓣膜再干预或死亡复合终点CABG+SAVR更优(14.2% vs 20.4%)。

核心结论

  • 合并冠心病的重度主动脉瓣狭窄患者中,CABG+SAVR围术期死亡高于PCI+TAVR,但5年风险校正后卒中、心梗、瓣膜再干预和死亡复合终点更低。

研究设计与样本

  • 基于美国医疗保险和医疗补助服务中心住院索赔数据库的回顾性队列研究,纳入2018至2022年65岁及以上合并冠心病的主动脉瓣狭窄患者。
  • 采用经验证指标校正合并症与衰弱,并使用逆概率加权、多水平回归和竞争风险时间事件分析进行双重稳健风险校正。
  • 研究队列共37822例,其中PCI+TAVR组17413例,CABG+SAVR组20409例。

主要发现

  • PCI+TAVR组围术期死亡1.1%,CABG+SAVR组3.6%(OR 0.29,P<.001)。
  • PCI+TAVR组血管并发症OR 6.02(P<.001),新永久起搏器OR 1.92(P<.001)。
  • 5年主要复合终点PCI+TAVR组20.4%,CABG+SAVR组14.2%(OR 1.44,P<.001)。
  • 亚组分析显示单支血管病变患者CABG+SAVR中使用动脉桥有获益。

临床怎么用

  • 临床决策需权衡PCI+TAVR较低的围术期死亡与较高的血管并发症、起搏器风险及远期复合终点。
  • 单支血管病变患者行CABG+SAVR时使用动脉桥可能带来获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As percutaneous therapeutic options expand, the optimal management of severe aortic stenosis (AS) and concomitant coronary artery disease (CAD) is being questioned between coronary artery bypass grafting with surgical aortic valve replacement (CABG+SAVR) and percutaneous coronary intervention with transcatheter aortic valve replacement (PCI+TAVR). This study sought to compare perioperative and longitudinal risk-adjusted outcomes between patients undergoing CABG+SAVR and patients undergoing PCI+TAVR. METHODS: Using the Centers for Medicare & Medicaid Services inpatient claims database, the study evaluated all patient aged 65 years and older with AS and CAD who were undergoing CABG+SAVR or PCI+TAVR (from 2018 to 2022). Comorbidities and frailty were accounted for using validated metrics with doubly robust risk adjustment using inverse probability weighting, multilevel regression, and competing-risk time to event analyses. The primary end point was a 5-year composite of stroke, myocardial infarction (MI), valve reintervention, or death. RESULTS: A total of 37,822 patients formed the study cohort (PCI+TAVR, n = 17,413; CABG+SAVR, n = 20,409). Accounting for age, comorbidities, frailty, and number of vessels revascularized, PCI+TAVR was associated with lower procedural mortality (1.1% vs 3.6%; odds ratio [OR], 0.29; P <.001) but higher vascular complications (OR, 6.02; P <.001) and new permanent pacemaker (OR, 1.92; P <.001). However, the longitudinal 5-year primary end point favored CABG+SAVR (20.4% vs 14.2%; OR, 1.44, P <.001). Subgroup analyses demonstrated a benefit in the use of arterial conduit in CABG+;AVR in patients with single-vessel CAD. CONCLUSIONS: Among Medicare beneficiaries with severe AS and CAD, CABG+SAVR was associated with higher procedural mortality than PCI+TAVR but lower 5-year risk-adjusted stroke, MI, valve reintervention, and death.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Jagadeesan V, Mehaffey JH, Kawsara MA, et al. Transcatheter vs Surgical Aortic Valve Replacement in Medicare Beneficiaries With Aortic Stenosis and Coronary Artery Disease. Ann Thorac Surg. 2025. PMID: 39864769. doi:10.1016/j.athoracsur.2024.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。